

Cervical Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C9EBF9BA466EN.html>

Date: May 2020

Pages: 1460

Price: US\$ 2,500.00 (Single User License)

ID: C9EBF9BA466EN

Abstracts

Cervical Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer – Pipeline Review, H1 2020, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 80, 75, 4, 46, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 2, 12 and 4 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on

mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Cervical Cancer - Overview

Cervical Cancer - Therapeutics Development

Cervical Cancer - Therapeutics Assessment

Cervical Cancer - Companies Involved in Therapeutics Development

Cervical Cancer - Drug Profiles

Cervical Cancer - Dormant Projects

Cervical Cancer - Discontinued Products

Cervical Cancer - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Cervical Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),
H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cervical Cancer - Pipeline by 3SBio Inc, H1 2020
Cervical Cancer - Pipeline by Aadi Bioscience Inc, H1 2020
Cervical Cancer - Pipeline by AbbVie Inc, H1 2020
Cervical Cancer - Pipeline by Abion Inc, H1 2020
Cervical Cancer - Dormant Projects, H1 2020
Cervical Cancer - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cervical Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc
Aadi Bioscience Inc
AbbVie Inc
Abion Inc
Abivax SA
Admedus Ltd
Advaxis Inc
Advenchen Laboratories LLC
Adze Biotechnology Inc
Affimed GmbH
Agenus Inc
Akeso Inc
Almac Discovery Ltd
Alphamab Oncology
amcure GmbH
Andes Biotechnologies
Anew Oncology Inc
AntiCancer Inc
Apimeds Inc
Apollomics Inc
Apotex Inc

Asana BioSciences LLC
Ascenta Therapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Beijing Neoantigen Biotechnology Co Ltd
Beijing Recreation Guards Biotechnology Co Ltd
BioAtla LLC
Biocad
BIOCND Inc
Biocon Ltd
BioIntegrator Ltd
Bioleaders Corp
Biomics Biotechnologies Co Ltd
BioNTech SE
Boehringer Ingelheim International GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellid Co Ltd
Centus Biotherapeutics Ltd
Changchun Bcht Biotechnology Co Ltd
Chineo Med Beijing Co Ltd
Chong Kun Dang Pharmaceutical Corp
Clovis Oncology Inc
Convert Pharmaceuticals SA
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
Cue Biopharma Inc
Cytocom Inc
CytomX Therapeutics Inc
CZ BioMed Corp
Daewon Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DeMar Pharmaceuticals Inc
Disulfican Ltd
EirGenix Inc

Eisai Co Ltd
Eli Lilly and Co
Epygen Biotech Pvt Ltd
Ervaxx Ltd
Etna Biotech Srl
Etubics Corp
Eubiologics Co Ltd
Exelixis Inc
EyeGene Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Five Prime Therapeutics Inc
Flow Pharma Inc
Fujifilm Holdings Corp
GamaMabs Pharma SA
Gene Techno Science Co Ltd
Genentech Inc
Genetic Immunity Inc
Genexine Inc
Genmab AS
Gilead Sciences Inc
GlaxoSmithKline Plc
GlycoNex Inc
Glycostem Therapeutics BV
GlyTR Therapeutics Inc
GO Therapeutics Inc
Gradalis Inc
Hamlet Pharma AB
Harbin Gloria Pharmaceuticals Co Ltd
Hefei Ruichengsheng Biotechnology Co Ltd
Hookipa Pharma Inc
Huabo Biopharm Co Ltd
ImCheck Therapeutics SAS
Immune Therapeutics Inc
Immunitor Inc
ImmunityBio Inc
Immunomedics Inc
IMV Inc
Incyte Corp

Innate Pharma SA
Innovene
Innovent Biologics Inc
InSight Biopharmaceuticals Ltd
Invectys SA
Iovance Biotherapeutics Inc
ISA Pharmaceuticals BV
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Komipharm International Co Ltd
Kymab Ltd
Medical Guidance Systems LLC
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
MicroQuin Ltd
Midissia Therapeutics Inc
Molecular Partners AG
Mundipharma EDO GmbH
Mycenax Biotech Inc
NeoTX Therapeutics Ltd
Newish Technology Beijing Co Ltd
Novartis AG
Noyan Pajouhan Biopharma
Ocellaris Pharma Inc
Onconova Therapeutics Inc
OncoSec Medical Inc
Ono Pharmaceutical Co Ltd
Oxford Vacmedix UK Ltd
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Phoenix Life Sciences International Ltd
PI Therapeutics Ltd
Plus Therapeutics Inc
Potenza Therapeutics Inc
Precigen Inc

Prestige BioPharma Pte Ltd
Puma Biotechnology Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
Richter Gedeon Nyrt
Samyang Holdings Corp
Sanofi
Savoy Pharmaceuticals Inc
Seattle Genetics Inc
Selecta Biosciences Inc
Shanghai Bovax Biotechnology Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Institute of Biological Products Co Ltd
Shanghai Zerun Biotechnology Co Ltd
Shantha Biotechnics Pvt Ltd
Shattuck Labs Inc
SK Bioscience
Sorrento Therapeutics Inc
Sotio AS
Spring Bank Pharmaceuticals Inc
SQZ Biotechnologies Co
Starpharma Holdings Ltd
Suzhou Stainwei Biotech Inc
Synermore Biologics Co Ltd
Takeda Pharmaceutical Co Ltd
TCRCure Biotech Co Ltd
Tessa Therapeutics Pte Ltd
Theralase Technologies Inc
Theravectys SA
THEVAX Genetics Vaccine USA Inc
Transgene SA
Turnstone Biologics Inc
Vaccibody AS
Vascular Biogenics Ltd
Vectorite Biomedical Inc
ViciniVax BV
Vir Biotechnology Inc
Virion Therapeutics LLC

Virometix AG
VLP The Vaccines Company SL
VM Discovery Inc
Wuhan Binhui Biotechnology Co Ltd
Xencor Inc
Xiamen Innovax Biotech Co Ltd
Zeria Pharmaceutical Co Ltd
Zhejiang Yangshengtang Biotech Co Ltd
Zymeworks Inc

I would like to order

Product name: Cervical Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C9EBF9BA466EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9EBF9BA466EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970